Physician profile
Bruce A Durham
NPI 1801116769
$459.38
in general payments reported to CMS, 2019-2025
11 companies · $65.22 in 2025
The $65.22 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.18 · 2020: $12.61 · 2021: $46.02 · 2022: $79.19 · 2023: $138 · 2024: $85.35 · 2025: $65.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $288.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $98.15 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $79.22 | 2022-2024 | Ubrelvy |
| Amgen INC. | $50.36 | 2019-2023 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $47.23 | 2023-2025 | Farxiga, Breztri |
| Phathom Pharmaceuticals, INC. | $43.18 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $41.45 | 2022-2023 | Mounjaro |
| Pfizer INC. | $29.79 | 2021-2023 | |
| Becton, Dickinson and Company | $22.45 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.79 | 2021 | |
| Endogastric Solutions, INC | $15.98 | 2024 | Esophyx |
| Astellas Pharma US INC | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Durham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.